What pneumococcal vaccination schedule is recommended for patients with heart failure, including the preferred vaccine and alternatives if PCV20 is unavailable?

Pneumococcal Vaccination for Heart Failure Patients

All patients with heart failure should receive pneumococcal vaccination, with PCV20 as a single dose being the preferred regimen for vaccine-naïve adults, completing the series without additional doses. 1

Why Heart Failure Patients Need Pneumococcal Vaccination

• Heart failure (including congestive heart failure and cardiomyopathies) is explicitly classified as a chronic medical condition requiring pneumococcal vaccination starting at age 19–64 years, not just at age ≥65. 1
• Patients with chronic heart disease face increased risk for pneumococcal community-acquired pneumonia and invasive disease, with mortality rates reaching up to 50% in high-risk populations. 1
• The 2014 AHA/ACC guidelines specifically recommend pneumococcal vaccine for high-risk cardiovascular patients, recognizing the substantial morbidity and mortality burden. 1

Preferred Vaccination Schedule by Age and Prior Vaccination Status

Adults ≥65 Years – Never Vaccinated

• Give a single dose of PCV20 (Prevnar20); this completes the pneumococcal series for life. 1, 2
• Alternative if PCV20 unavailable: Give PCV15 (VAXNEUVANCE) followed by PPSV23 (Pneumovax23) ≥1 year later. 1, 2
• PCV21 (CAPVAXIVE) is also an acceptable option as of 2024, though PCV20 remains most widely recommended. 1

Adults 19–64 Years with Heart Failure – Never Vaccinated

• Give a single dose of PCV20 alone, completing the series. 1
• Alternative: Give PCV15 followed by PPSV23 ≥1 year later (standard 1-year interval for immunocompetent patients). 1
• Re-evaluate vaccination status when the patient turns 65 to determine if additional doses are needed based on prior history. 1

If Patient Previously Received PPSV23 Only

• Give PCV20 ≥1 year after the last PPSV23 dose; this completes the series. 1, 2
• The same ≥1 year interval applies regardless of age or whether PPSV23 was given before or after age 65. 2, 3

If Patient Previously Received PCV13 Only

• Give PCV20 ≥1 year after the PCV13 dose; this completes the series. 1
• Alternative: Give PPSV23 ≥1 year after PCV13. 1

If Patient Previously Received Both PCV13 and PPSV23

• For adults <65 years: No additional vaccines are needed until age 65; reassess at that time. 1
• For adults ≥65 years who completed PCV13 + PPSV23 at age ≥65: No routine additional vaccines are recommended. 1, 2
• Optional consideration: Shared clinical decision-making may support giving PCV20 ≥5 years after the last pneumococcal dose in select cases. 1

Critical Timing Intervals

Scenario	Minimum Interval	Citation
PCV → PPSV23 (heart failure patients)	≥1 year	[1]
PPSV23 → PCV (any patient)	≥1 year	[1,2]
PCV13 → PCV20	≥1 year	[1]

• Never co-administer PCV and PPSV23 on the same day—this reduces immune response and wastes vaccine. 2, 4

If PCV20 Is Unavailable

• Use PCV21 (CAPVAXIVE) as an alternative single-dose option with the same timing intervals. 1
• Use PCV15 followed by PPSV23 ≥1 year later if neither PCV20 nor PCV21 is available. 1, 2
• Important caveat: PCV21 does not contain serotype 4, which causes ≥30% of invasive pneumococcal disease in certain western U.S. populations (Alaska, Navajo Nation); in these regions, prefer PCV20 over PCV21. 1

Common Pitfalls and How to Avoid Them

• Do not delay vaccination waiting for complete medical records—use verbal history and proceed with indicated vaccination. 2, 4
• Do not give multiple PPSV23 boosters beyond recommendations—adults who receive PPSV23 at age ≥65 should receive only one dose; no additional PPSV23 doses are recommended after that. 1, 2, 4
• Once PCV20 is administered, the pneumococcal series is complete—additional PPSV23 is not recommended. 2, 4
• Heart failure patients do not require the shortened 8-week interval between PCV and PPSV23 (that interval applies only to immunocompromised patients such as those with chronic renal failure, asplenia, HIV, or on immunosuppressive therapy). 1
• Document vaccination clearly to avoid unnecessary future doses, but never withhold vaccination due to missing records. 2, 4

Special Considerations for Heart Failure Patients

• Influenza vaccination is also strongly recommended for all heart failure patients annually, as influenza vaccine reduces all-cause mortality, cardiovascular mortality, and cardiovascular events in patients with cardiovascular disease. 1
• Pneumococcal vaccination is recommended regardless of ejection fraction or heart failure severity, as chronic heart disease (including congestive heart failure and cardiomyopathies) is a recognized indication. 1
• Patients with heart failure who are also on immunosuppressive therapy (e.g., post-transplant) should follow the immunocompromised vaccination schedule with an 8-week interval between PCV and PPSV23. 1

Duration of Protection

• For adults ≥65 years, current pneumococcal vaccines are considered lifetime vaccinations—no routine booster doses are recommended after completion of the series. 2, 4
• The PPSV23 dose given at age ≥65 years is the final pneumococcal vaccine—no additional boosters are recommended. 2, 4